Sage Therapeutics Inc. Watch

from 10-Q 2 pages Sage Therapeutics, Inc. Amendment No. 1 to Amended and Restated 2016 Inducement Equity Plan

from 10-Q 5 pages Sage Therapeutics, Inc. Non-Employee Director Compensation Program

from 10-Q 6 pages Sage Therapeutics, Inc. Stock Option Agreement Granted Under 2024 Equity Incentive Plan

from 10-Q 9 pages Sage Therapeutics, Inc. Restricted Stock Unit Agreement Granted Under 2024 Equity Incentive Plan

from 10-Q 6 pages Sage Therapeutics, Inc. Stock Option Agreement Granted Under 2024 Equity Incentive Plan

from 10-Q 19 pages The Purpose of This 2024 Equity Incentive Plan (The “Plan”) of Sage Therapeutics, Inc., a Delaware Corporation (The “Company”), Is to Advance the Interests of the Company’s Stockholders by Enhancing the Company’s Ability to Attract, Retain and Motivate Persons Who Are Expected to Make Important Contributions to the Company and by Providing Such Persons With Equity Ownership Opportunities and Performance-Based Incentives That Are Intended to Better Align the Interests of Such Persons With Those of the Company’s Stockholders. Except Where the Context Otherwise Requires, the Term “Company” Shall Include Any of the Company’s Present or Future Parent or Subsidiary Corporations as Defined in Sections 424(e) or (F) of the Internal Revenue Code of 1986, as Amended, and Any Regulations Thereunder (The “Code”) and Any Other Business Venture (Including, Without Limitation, Joint Venture or Limited Liability Company) in Which the Company Has a Controlling Interest, as Determined by the Board of Directors of the Company (The “Board”). 2. Eligibility

from 10-Q 8 pages Severance and Change in Control Agreement

from 10-Q 3 pages August 6, 2015 Confidential Anne Marie Cook Dear Anne Marie

from 10-Q 123 pages Office Lease Agreement Between 55 Cambridge Parkway, LLC, a Delaware Limited Liability Company, as Landlord and Sage Therapeutics, Inc., a Delaware Corporation, as Tenant at 55 Cambridge Parkway, Cambridge, Ma

from 8-K 1 page Sage Therapeutics, Inc. Amendment No. 1 to Amended and Restated 2016 Inducement Equity Plan

from 10-Q 13 pages Master Consulting Agreement

from 10-Q 14 pages August 30, 2023 Revised September 15, 2023 by Email

from 10-Q 17 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. […***…] Denotes Omissions. Exclusive License Agreement Preamble

from 10-Q 17 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. […***…] Denotes Omissions. Non-Exclusive License Agreement Between the Regents of the University of California and Sage Therapeutics, Inc. for Allopregnanolone in the Treatment of Status Epilepticus and Post-Partum Depression File No. […***…]

from 10-Q 24 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. […***…] Denotes Omissions. Commercial License Agreement This Commercial License Agreement (This “Agreement”) Is Made This 21st Day of August, 2013 (The “Effective

from 10-Q 6 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. […***…] Denotes Omissions

from 10-Q 20 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. […***…] Denotes Omissions. Supply Agreement Recitals

from 10-Q 6 pages Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan, as Amended

from 10-Q 4 pages Performance-Based Restricted Stock Unit Award Agreement Under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan

from 10-Q 5 pages Sage Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy